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Abstract
Background: Previous studies have suggested that there may be an association between vitamin D deficiency and
the risk of developing immune-mediated diseases.
Methods: We analyzed a database of linked statistical records of hospital admissions and death registrations for the
whole of England (from 1999 to 2011). Rate ratios for immune-mediated disease were determined, comparing
vitamin D deficient cohorts (individuals admitted for vitamin D deficiency or markers of vitamin D deficiency) with
comparison cohorts.
Results: After hospital admission for either vitamin D deficiency, osteomalacia or rickets, there were significantly
elevated rates of Addison’s disease, ankylosing spondylitis, autoimmune hemolytic anemia, chronic active hepatitis,
celiac disease, Crohn’s disease, diabetes mellitus, pemphigoid, pernicious anemia, primary biliary cirrhosis,
rheumatoid arthritis, Sjogren’s syndrome, systemic lupus erythematosus, thyrotoxicosis, and significantly reduced
risks for asthma and myxoedema.
Conclusions: This study shows that patients with vitamin D deficiency may have an increased risk of developing
some immune-mediated diseases, although we cannot rule out reverse causality or confounding. Further study of
these associations is warranted and these data may aid further public health studies.
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Background
Immune-mediated diseases cumulatively represent one
of the most common chronic disease groups in medicine
today, affecting approximately 10% of first world popula-
tions [1]. There is substantial evidence in support of
these disorders being determined by both genetic and
environmental factors. One candidate environmental risk
factor implicated in immune-mediated disease suscepti-
bility is vitamin D deficiency [2-4].
Historically, vitamin D was thought to play a restricted
role in calcium homeostasis; however, a wealth of studies
now suggests that it exerts more widespread effects
[5,6]. Functional laboratory studies have shown that vita-
min D can modulate the immune response [5,6] and a
number of epidemiological findings have implicated the
involvement of vitamin D deficiency in the risk of deve-
loping immune-mediated diseases [2-4]. These include
the ecological findings of the prevalence of diseases,
such as multiple sclerosis (MS), type 1 diabetes, inflam-
matory bowel disease, rheumatoid arthritis and Sjogren’s
syndrome, positively correlating with latitude and re-
duced ultraviolet radiation exposure (the primary deter-
minant of vitamin D levels) [1]. Further support comes
from studies showing low serum vitamin D levels in pa-
tients suffering from a wide range of immune disorders,
including MS [7], type 1 diabetes [8], systemic lupus
erythematosus (SLE) [9] and rheumatoid arthritis [10].
These findings may, however, be biased by reverse causa-
tion [11].
To investigate further any association between vitamin
D and immune-mediated disease, we undertook record
linkage studies to determine the risk of immune-mediated
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disease in individuals admitted for vitamin D deficiency or
a marker of vitamin D deficiency (rickets or osteomalacia)




We used a linked English national dataset of hospital
admissions (Hospital Episode Statistics (HES)) and mor-
tality. HES data are records of hospital care that are
compiled for every episode of day case care or hospital
admission in all English National Health Service (NHS)
hospitals, and were supplied by the English national In-
formation Centre for Health and Social Care. The mor-
tality data were derived from death certificates and were
supplied by the Office for National Statistics. The linked
dataset used in this study, in which successive records
for each individual were linked together, was constructed
by the Oxford record linkage group.
The International Classification of Disease (ICD) codes
used for the vitamin D related conditions were osteo-
malacia (M83.1, M83.8, M83.9), rickets (E55.0, E64.3)
and vitamin D deficiency (E55.9). The ICD codes used
for the immune-mediated diseases were Addison’s dis-
ease (E27.1), ankylosing spondylitis (M45), asthma (J45),
autoimmune hemolytic anemia (D59.1), chronic active
hepatitis (K73.2), Crohn’s disease (K50), celiac disease
(K90.0), dermatomyositis (M33.0 to M33.1), diabetes
mellitus (E10 to E14), polymyositis (M33.2), Goodpasture’s
syndrome (M31.0), Hashimoto’s thyroiditis (E06.3), idio-
pathic thrombocytopenia purpura (D69.3), multiple scler-
osis (G35), myasthenia gravis (G70.0), myxoedema (E03.8
to E03.9), pemphigus (L10), pemphigoid (L12), pernicious
anemia (D51.0), polyarteritis nodosa (M30.0), primary bil-
iary cirrhosis (K74.3), psoriasis (L40), rheumatoid arthritis
(M05 to M06), scleroderma (M34), Sjogren’s syndrome
(M35.0), SLE (M32.1 to M32.9), thyrotoxicosis (E05), and
ulcerative colitis (K51). In the analysis of diabetes mellitus,
we used hospital admission for diabetes mellitus when the
patient was aged under 30 as a proxy for type 1 diabetes,
as the type of diabetes is not well recorded in routine hos-
pital statistics. We also confined the analysis of asthma ad-
missions to people aged between the ages of 5 and 54 to
reduce potential issues with misclassification of asthma-
like respiratory conditions in younger and older people.
The methods of analysis were the same for all vitamin
D-related admissions and immune-mediated diseases;
we describe the methods for rickets and Crohn’s disease
as the example. A cohort of people with rickets was
constructed for those with a diagnosis of rickets as a
reason for hospital care, by identifying the first episode
of day case care, or admission, for rickets during the
study period. A reference cohort was constructed by
identifying the first admission for each individual with
various other, mainly minor medical and surgical, con-
ditions (listed in the Table 1 legend), as in previous
studies of disease associations [12]. Standard epidemio-
logical practice was followed by selecting a diverse range
of conditions rather than relying on a limited range (in
case the latter are themselves atypical in their risk of
immune-mediated disease) [12]. As a check, we studied
the risk of immune-mediated disease in the control con-
ditions within the reference cohort to ensure that the
reference cohort did not include control conditions that
have atypically high or low immune mediated-disease
rates. For some immune-mediated diseases (for example,
rheumatoid arthritis), we removed some control con-
ditions (for example, hip/knee replacement) from the
reference cohort where we considered that this may
otherwise have skewed the findings. For the fairly small
number of associations affected by this, we show the ‘ad-
justed’ associations (that is, with some control condi-
tions removed) for these diseases in the main paper; for
completeness and comparison, the unadjusted associa-
tions are also provided (see below). Anyone with both
an ‘exposure’ disease, for example, Crohn’s disease, and
a reference cohort condition was included in the expo-
sure cohort and excluded from the reference cohort.
People were included in the rickets or reference cohort
if they did not have an admission for an immune-
mediated disease either before or at the same time as
the admission for rickets or the reference condition. The
database was then investigated for any subsequent NHS
hospital care for, or death from, Crohn’s disease in these
cohorts. We considered that rates of Crohn’s disease in
the reference cohort would approximate those in the
general population while allowing for migration as data
on migration of individuals were not available.
The analysis was performed using a suite of programs
developed ‘in house’ using SAS 9 software (SAS Institute,
Cary, NC, USA).
Ethical approval
The construction and analysis of the datasets were un-
dertaken with the approval of the Central and South
Bristol Research Ethics Committee (REC, reference 04/
Q2006/175).
Statistical methods
Rates of Crohn’s disease were calculated based on person-
years. Date of entry into each cohort was the date of the
first admission for rickets, or reference condition, and date
of exit was the date of the first record of Crohn’s disease,
death or the end of data collection (28 February 2011),
whichever was the earliest. We first calculated rates for
Crohn’s disease, stratified and then standardized by age (in
five-year age groups), sex, calendar year of first recorded
admission, region of residence, and quintile of patients’
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Index of Deprivation score (a standard English measure of
socio-economic status). The indirect method of standar-
dization was used, with the combined rickets and refer-
ence cohorts as the standard population. We applied the
stratum-specific rates in the standard population to the
number of people in each stratum in the rickets cohort
and then, separately, to those in the same stratum in the
reference cohort, to obtain the expected number of people
with Crohn’s disease in each stratum of the rickets and
reference cohort. Observed and expected numbers were
then summed across all strata to give totals for all strata
combined. Rate ratios were calculated by taking the stan-
dardized rate of occurrence of Crohn’s disease in the
rickets cohort relative to the reference cohort using the
formula (Orickets/Erickets)/(Oref/Eref ), where O and E are
the observed and expected numbers of Crohn’s disease
cases in the rickets and reference cohorts, respectively. In
each table, we only show diseases in which either the ob-
served or expected number, or both were five or more.
The confidence interval for the rate ratio of Crohn’s and
χ2 statistics for its significance were calculated as des-
cribed elsewhere [13].
Results
The number of people in the cohort with vitamin D defi-
ciency was 13,260 (71.5% female), osteomalacia 5,191
(69.4% female), and rickets 1,228 (59.5% female). Age
Table 1 Age-distribution of people in exposure cohorts, percentage who were female, and numbers in reference
cohort1
Exposure condition Age at admission N in the exposure
cohort (% of total)
% female Number in the
reference cohort2
Rickets, osteomalacia, or vitamin D
deficiency, all combined:
<15 745 (7.5) 53.0 889,364
15 to 44 532 (24) 72.4 2,906,048
45 to 64 1,191 (26.7) 70.4 2,206,093
65 to 74 1,356 (15.1) 68.9 1,198,951
75+ 1,697 (26.7) 73.1 1,403,767
All ages 19,338 (100) 70.1 8,604,223
Rickets: <15 494 (54.8) 48.9 889,495
15 to 44 73 (16.8) 70.4 2,907,044
45 to 64 32 (8.7) 71.0 2,207,541
65 to 74 29 (7) 68.6 1,200,051
75+ 42 (12.7) 78.2 1,405,341
All ages 1,228 (100) 59.5 8,609,472
Osteomalacia: <15 1 (0.1) 0.0 889,562
15 to 44 39 (16.9) 68.8 2,906,823
45 to 64 275 (30.3) 62.7 2,207,108
65 to 74 503 (20.5) 68.3 1,199,703
75+ 585 (32.2) 76.7 1,404,882
All ages 5,191 (100) 69.4 8,608,078
Vitamin D deficiency: <15 263 (6) 56.8 889,428
15 to 44 436 (27.5) 73.5 2,906,311
45 to 64 911 (26.9) 74.0 2,206,566
65 to 74 847 (13.8) 69.5 1,199,332
75+ 1,107 (25.8) 71.5 1,404,315
All ages 13,260 (100) 71.5 8,605,952
1 The reference cohort consisted of people admitted with the following conditions coded under the Office of Population, Censuses and Surveys (OPCS) code
edition 4 for operations and ICD10 code for diagnosis (with equivalent codes used for other coding editions): appendectomy (OPCS4 H01 to H03), adenoidectomy
(E20), tonsillectomy (F34 + F36), dilation and curettage (Q10.3 + Q11.4), total hip replacement (W37 to W39), total knee replacement (W40 to W42), squint (ICD10
H49 to H51), cataract (H25), otitis externa/media (H60 to H67), varicose veins (I83), hemorrhoids (I84), deflected septum, nasal polyp (J33 + J34.2), impacted tooth
and other disorders of teeth (K00 to K03), inguinal hernia (K40), in-growing nail, toenail and other diseases of the nails (L60), sebaceous cyst (L72.1), bunion
(M20.1), internal derangement of the knee (M23), dislocations, sprains and strains (S03, S13, S23, S33, S43, S53, S63, S73, S83, S93), selected limb fractures (S42,
S52, S62, S82, S92), superficial injury and contusion (S00, S10, S20, S30, S40, S50, S60, S70, S80, S90), contraceptive management (Z30).
2 The numbers in the reference cohort vary slightly depending on what the exposure condition is. This is because individuals, who otherwise fulfilled the criteria
for inclusion in the reference cohort, were removed from the reference cohort if they fulfilled the criteria for inclusion in the exposure cohort (see Methods).
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distributions are shown in Table 1. There were more
than 8.6 million people in the reference cohort.
There were significantly elevated risks of Addison’s
disease, ankylosing spondylitis, autoimmune hemolytic
anemia, chronic active hepatitis, celiac disease, Crohn’s
disease, diabetes mellitus, pemphigoid, pernicious anemia,
primary biliary cirrhosis, rheumatoid arthritis, Sjogren’s
syndrome, systemic lupus erythematosus, thyrotoxicosis;
and significantly reduced risks for asthma and myxoedema
after hospital admission for either vitamin D deficiency,
osteomalacia or rickets (Table 2).
There were significantly elevated risks of celiac di-
sease, pernicious anemia and thyrotoxicosis after hospital
admission for rickets (Table 3). Celiac disease had a sub-
stantially increased risk.
There were significantly elevated risks of Addison’s
disease, celiac disease, diabetes mellitus, Sjogren’s syn-
drome and thyrotoxicosis; and significantly reduced risks
for asthma and myxoedema after hospital admission for
osteomalacia (Table 4). The rate ratios for Addison’s
disease, and celiac disease were particularly high. There
were significantly elevated rates of Addison’s disease,
celiac disease, Crohn’s disease, diabetes mellitus, pem-
phigoid, pernicious anemia, primary biliary cirrhosis,
rheumatoid arthritis, Sjogren’s syndrome, SLE and thyro-
toxicosis; and significantly reduced rates for asthma and
myxoedema after hospital admission for vitamin D de-
ficiency (Table 5). Again, the rate ratios for Addison’s
disease and celiac disease were particularly high, as was
the rate ratio for SLE.
Unadjusted associations when done, see Methods, are
shown in Table 6.
Discussion
We present evidence associating vitamin D deficiency
(or proxies of vitamin D deficiency) with risks of or pro-
tection against developing subsequent immune-mediated
disease. Previous studies have linked inherited forms of
rickets with MS [14] and type 1 diabetes [15], but no
study has attempted an analysis similar to the one we
present here. Addison’s disease and thyrotoxicosis were
significantly associated in all analyses, and asthma was
significantly low in all but one. The combined analysis
found associations with a greater number of immune-
mediated diseases - a lack of significance in the individ-
ual rickets, osteomalacia or vitamin D deficiency cohorts
may reflect the lower power of these individual analyses.
The associations described warrant further attention.
Mechanistically, it is possible that vitamin D deficiency
predisposes to the development of immune-mediated
disease by perturbing the immune response [2]. Another
explanation is reverse causality - that the disease (either
sub-clinically or clinically present but not recorded with
a hospital admission prior to the vitamin D deficiency
Table 2 Rate ratios for immune-mediated diseases
following admission for rickets, osteomalacia or vitamin
D deficiency, combined
Disease O E RR (95% CI) P-value
Addison’s disease 21 3 7.2 (4.4 to 11.0) <0.001
Ankylosing spondylitis1 16 8.2 2.0 (1.1 to 3.2) 0.01
Asthma (aged 5 to 54)2 150 375.5 0.4 (0.3 to 0.5) <0.001
Autoimmune hemolytic anemia 6 2.2 2.7 (1.0 to 5.9) 0.03
Chronic active hepatitis 6 1 6.2 (2.3 to 13.5) <0.001
Celiac disease3 78 14.3 5.5 (4.3 to 6.9) <0.001
Crohn’s disease3 47 17.9 2.6 (1.9 to 3.5) <0.001
Diabetes mellitus (aged 0 to 29)4 7 1.8 3.9 (1.6 to 8.1) <0.001
Hashimoto’s 6 2.8 2.1 (0.8 to 4.6) 0.11
Idiopathic thrombocyt. purpura 11 8.3 1.3 (0.7 to 2.4) 0.44
Multiple sclerosis5 15 13.1 1.1 (0.6 to 1.9) 0.7
Myxoedema 335 520.4 0.6 (0.6 to 0.7) <0.001
Pemphigoid 13 4.9 2.7 (1.4 to 4.5) 0.001
Pernicious anemia 60 35.7 1.7 (1.3 to 2.2) <0.001
Polymyositis 5 1 5.1 (1.6 to 11.9) <0.001
Primary biliary cirrhosis 12 4.4 2.8 (1.4 to 4.8) 0.001
Psoriasis 29 44.2 0.7 (0.4 to 0.9) 0.03
Rheumatoid arthritis1 158 126.2 1.3 (1.1 to 1.5) 0.005
Scleroderma 6 3.4 1.8 (0.7 to 3.9) 0.25
Sjogren’s syndrome 20 9.4 2.1 (1.3 to 3.3) 0.001
Systemic lupus erythematosus 33 8.1 4.1 (2.8 to 5.8) <0.001
Thyrotoxicosis 100 57.7 1.7 (1.4 to 2.1) <0.001
Ulcerative colitis3 32 25.2 1.3 (0.9 to 1.8) 0.21
O Observed number of cases, E Expected number, RR Rate ratio,
95% CI 95% Confidence interval.
1Hip replacement and knee replacement were excluded from the
reference cohort.
2Nasal polyp and deflected septum were excluded from the reference cohort.
3Hemorrhoids, appendectomy and cholelithiasis were excluded from the
reference cohort.
4Cataracts were excluded from the reference cohort.
5Limb fractures, dislocations, superficial injury, squint and head injury were
excluded from the reference cohort.
Diseases studied, but with fewer than five observed cases: dermatomyositis,
Goodpasture’s syndrome, myasthenia gravis, pemphigus, polyarteritis nodosa.
Table 3 Rate ratios for immune-mediated diseases
following admission for rickets
Disease O E RR (95% CI) P-value
Asthma (aged 5 to 54) 21 32.7 0.6 (0.4 to 1.0) 0.05
Celiac disease 10 1 10.3 (4.9 to 18.9) <0.001
Myxoedema 26 17.7 1.5 (1.0 to 2.2) 0.06
Pernicious anemia 6 1.6 3.7 (1.4 to 8.0) 0.002
Rheumatoid arthritis 9 5 1.8 (0.8 to 3.4) 0.12
Thyrotoxicosis 7 2.1 3.4 (1.4 to 6.9) 0.002
O Observed number of cases; E Expected number, RR Rate ratio,
95% CI 95% confidence interval.
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admission) reduces vitamin D levels as a result of an in-
flammatory state and/or causes the individual to spend
less time outdoors [16]. The increasing awareness of
vitamin D may also lead to an increase in requests for
vitamin D testing, and subsequent diagnosis of vitamin
D deficiency [17]. However, under either of these hy-
potheses the apparent protective effects of vitamin D de-
ficiency on asthma and myxoedema are not easy to
reconcile. There are reports, however, that state that
higher levels of vitamin D in childhood may increase the
risk of asthma [18,19]. For disorders such as celiac dis-
ease there may be an issue with regards to intake and/or
malabsorption of vitamin D; with Addison’s disease,
glucocorticoid deficiency may lead to suppression of the
parathyroid hormone-vitamin D axis [20].
The study has limitations. It is not a prospective co-
hort with follow-up from the date of “first ever” diagno-
sis, but just from “first recorded” diagnosis in a hospital
day case or inpatient record. Data are not recorded on
patients who move out of the area covered by data col-
lection or who are treated in hospitals outside the area.
The dataset is limited to people who were admitted to
hospital, or who received day case specialist care, and
thus there exists the potential for selection bias. There
is very limited information on potential confounding
factors, such as detailed socioeconomic characteristics,
ethnicity and smoking. The effect of making multiple
comparisons needs to be considered. It is possible that
some of the associations that are significant may result
from making multiple comparisons and the play of
chance. To aid assessment of this, we have provided
P-values so that readers can judge where P-values are
extreme: for example, with P-values as high as <0.001
for the associations between the vitamin D related con-
ditions, combined, and celiac and Crohn’s disease, the
associations are unlikely to be chance alone.
Table 4 Rate ratios for immune-mediated diseases
following admission for osteomalacia
Disease O E RR (95% CI) P-value
Addison’s disease 9 1.1 8.1 (3.7 to 15.4) <0.001
Ankylosing spondylitis 5 2.9 1.7 (0.57 to 4.1) 0.33
Asthma (aged 5 to 54) 50 71.9 0.7 (0.5 to 0.9) 0.01
Celiac disease 32 4.9 6.5 (4.4 to 9.2) <0.001
Crohn’s disease 12 7.1 1.7 (0.9 to 3.0) 0.10
Diabetes mellitus (aged 0 to 29) 11 3.8 2.9 (1.5 to 5.2) 0.001
Idiopathic thrombocyt. purpura 5 2.9 1.8 (0.6 to 4.1) 0.33
Myxoedema 143 185.8 0.8 (0.7 to 0.9) 0.002
Pernicious anemia 23 15.1 1.5 (1.0 to 2.3) 0.06
Primary biliary cirrhosis 5 1.9 2.7 (0.9 to 6.3) 0.05
Psoriasis 11 14.6 0.8 (0.4 to 1.4) 0.42
Rheumatoid arthritis 54 49.3 1.1 (0.8 to 1.4) 0.55
Sjogren’s syndrome 8 3.7 2.2 (0.9 to 4.3) 0.04
Thyrotoxicosis 30 20.8 1.4 (1.0 to 2.1) 0.06
Ulcerative colitis 11 10.7 1.0 (0.5 to 1.9) 0.96
O Observed number of cases, E Expected number, RR Rate ratio,
95% CI 95% confidence interval.
Table 5 Rate ratios for immune-mediated diseases
following admission for vitamin D deficiency
(coded as such)
Autoimmune condition O E RR (95% CI) P-value
Addison’s disease 12 1.7 7.0 (3.6 to 12.3) <0.001
Ankylosing spondylitis 10 5.3 1.9 (0.9 to 3.5) 0.06
Asthma (aged 5 to 54) 83 278.9 0.3 (0.2 to 0.4) <0.001
Celiac disease 38 8.6 4.4 (3.1 to 6.1) <0.001
Crohn’s disease 33 10 3.3 (2.3 to 4.6) <0.001
Diabetes mellitus (aged 0 to 29) 20 6.2 3.2 (2.0 to 5.0) <0.001
Idiopathic thrombocyt. purpura 5 5 1.0 (0.3 to 2.3) 0.83
Multiple sclerosis 12 8.2 1.5 (0.8 to 2.6) 0.25
Myxoedema 177 328.2 0.5 (0.5 to 0.6) <0.001
Pemphigoid 10 2.7 3.7 (1.8 to 6.8) <0.001
Pernicious anemia 34 19.6 1.7 (1.2 to 2.4) 0.002
Primary biliary cirrhosis 7 2.4 2.9 (1.2 to 6.0) 0.008
Psoriasis 18 28.9 0.6 (0.4 to 1.0) 0.05
Rheumatoid arthritis 101 74.5 1.4 (1.1 to 1.7) 0.003
Sjogren’s syndrome 12 5.7 2.1 (1.1 to 3.7) 0.01
Systemic lupus erythematosus 28 5.3 5.3 (3.5 to 7.7) <0.001
Thyrotoxicosis 67 35.9 1.9 (1.5 to 2.4) <0.001
Ulcerative colitis 21 13.6 1.5 (0.9 to 2.3) 0.06
O Observed number of cases, E Expected number, RR Rate ratio,
95% CI 95% confidence interval.
Table 6 Unadjusted* RRs for immune-mediated diseases
following admission for rickets, osteomalacia or vitamin
D deficiency, combined
Autoimmune condition O E RR (95% CI) P-value
Ankylosing spondylitis 16 9.3 1.73 (0.99 to 2.81) 0.04
Asthma (aged 5 to 54) 150 393 0.38 (0.32 to 0.45) <0.001
Celiac disease 78 15.8 4.96 (3.91 to 6.19) <0.001
Crohn’s disease 47 23.2 2.03 (1.49 to 2.7) <0.001
Diabetes mellitus
(aged 0 to 29)
20 6.3 3.2 (1.96 to 4.95) <0.001
Multiple sclerosis 15 16.4 0.92 (0.51 to 1.51) 0.826
Rheumatoid arthritis 158 147.2 1.07 (0.91 to 1.25) 0.397
Ulcerative colitis 32 28.9 1.11 (0.76 to 1.56) 0.626
O Observed number of cases, E Expected number, RR Rate ratio,
95% CI 95% confidence interval.
* See Methods section and legend for Table 2.
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Conclusions
Our results should be regarded as speculative. Further
studies should look at individual immune-mediated dis-
eases in greater depth to confirm or refute the findings
and investigate mechanisms behind any association. Re-
gardless of the direction of causality, the fact that indi-
viduals with immune-mediated disease are at risk of
vitamin D deficiency is of note to ensure they are made
replete to support adequate bone health [2].
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